Arsanis (ASNS) Stock Rating Lowered by Zacks Investment Research

Arsanis (NASDAQ:ASNS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company’s product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. “

How to Become a New Pot Stock Millionaire

Other analysts have also issued reports about the company. Cantor Fitzgerald set a $26.00 price target on Arsanis and gave the stock a “buy” rating in a research note on Thursday, March 15th. ValuEngine raised Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Citigroup started coverage on Arsanis in a research note on Monday, December 11th. They issued a “buy” rating and a $27.00 price objective on the stock. Piper Jaffray Companies started coverage on Arsanis in a research note on Monday, December 11th. They issued an “overweight” rating and a $23.00 price objective on the stock. Finally, Cowen started coverage on Arsanis in a research note on Monday, December 11th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $26.25.

Shares of Arsanis (NASDAQ:ASNS) opened at $24.50 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.45 and a quick ratio of 7.45. Arsanis has a 52 week low of $10.40 and a 52 week high of $28.69.

Arsanis (NASDAQ:ASNS) last issued its quarterly earnings results on Friday, March 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.82). research analysts predict that Arsanis will post -5.23 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Monashee Investment Management LLC acquired a new position in shares of Arsanis in the 4th quarter valued at about $191,000. Millennium Management LLC acquired a new position in shares of Arsanis in the 4th quarter valued at about $299,000. Landscape Capital Management L.L.C. acquired a new position in shares of Arsanis in the 4th quarter valued at about $504,000. Finally, Sphera Funds Management LTD. acquired a new position in shares of Arsanis in the 4th quarter valued at about $3,436,000. 69.45% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Arsanis (ASNS) Stock Rating Lowered by Zacks Investment Research” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3297918/arsanis-asns-stock-rating-lowered-by-zacks-investment-research.html.

About Arsanis

Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Park-Ohio Holdings Corp.  Given Average Recommendation of “Hold” by Brokerages
Park-Ohio Holdings Corp. Given Average Recommendation of “Hold” by Brokerages
Contrasting resTORbio  and BioLineRx
Contrasting resTORbio and BioLineRx
Contrasting MarineMax  & U.S. Auto Parts
Contrasting MarineMax & U.S. Auto Parts
Target  and Its Rivals Critical Review
Target and Its Rivals Critical Review
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Formula Systems  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Formula Systems Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact SandRidge Energy  Share Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact SandRidge Energy Share Price


© 2006-2018 Ticker Report. Google+.